A citation-based method for searching scientific literature


List of co-cited articles
59 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
22

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
18

Immune checkpoint inhibitors in melanoma.
Matteo S Carlino, James Larkin, Georgina V Long. Lancet 2021
103
18

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
18

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J Gogas, Christopher D Lao, Juliana Janoski De Menezes,[...]. N Engl J Med 2022
168
18

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
18

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
13

Enhancing cancer immunotherapy with nanomedicine.
Darrell J Irvine, Eric L Dane. Nat Rev Immunol 2020
231
13

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu. Mol Cancer 2022
55
13

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Bogdan Zurawski, Victor M Oyervides Juárez, James J Hsieh, Umberto Basso, Amishi Y Shah,[...]. N Engl J Med 2021
434
13

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
Andrea Cercek, Melissa Lumish, Jenna Sinopoli, Jill Weiss, Jinru Shia, Michelle Lamendola-Essel, Imane H El Dika, Neil Segal, Marina Shcherba, Ryan Sugarman,[...]. N Engl J Med 2022
78
13

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
9

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald P Linette, Nicolas Meyer, Jeffrey K Giguere, Sanjiv S Agarwala,[...]. N Engl J Med 2015
9

Melanoma Risk Factors and Prevention.
William W Dzwierzynski. Clin Plast Surg 2021
7
28


Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
9

Resistance to BRAF-targeted therapy in melanoma.
Ryan J Sullivan, Keith T Flaherty. Eur J Cancer 2013
258
9

Recent Advances in the Treatment of Melanoma.
Brendan D Curti, Mark B Faries. N Engl J Med 2021
72
9

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
9

Immune checkpoint inhibitors: recent progress and potential biomarkers.
Pramod Darvin, Salman M Toor, Varun Sasidharan Nair, Eyad Elkord. Exp Mol Med 2018
905
9

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
9

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, Margaret K Callahan, Michael A Postow, Naiyer A Rizvi, Alexander M Lesokhin, Neil H Segal, Charlotte E Ariyan, Ruth-Ann Gordon, Kathleen Reed,[...]. N Engl J Med 2013
9

Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison. Science 1996
9

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
9

Immune-related adverse events and the balancing act of immunotherapy.
Michael Conroy, Jarushka Naidoo. Nat Commun 2022
19
10

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Evan Y Yu, Daniel P Petrylak, Peter H O'Donnell, Jae-Lyun Lee, Michiel S van der Heijden, Yohann Loriot, Mark N Stein, Andrea Necchi, Takahiro Kojima, Michael R Harrison,[...]. Lancet Oncol 2021
45
9

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
9

Physical traits of cancer.
Hadi T Nia, Lance L Munn, Rakesh K Jain. Science 2020
149
9

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia. J Hematol Oncol 2022
26
9

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.
Golnaz Morad, Beth A Helmink, Padmanee Sharma, Jennifer A Wargo. Cell 2021
120
9

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
9

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
9

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
9

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
9

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
506
9

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, Alena Gros, Paul F Robbins, Yong-Chen Lu, Mark E Dudley, John R Wunderlich, Robert P Somerville, Katherine Hogan, Christian S Hinrichs,[...]. Science 2014
9

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Kristian M Hargadon, Coleman E Johnson, Corey J Williams. Int Immunopharmacol 2018
552
9

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima. Front Oncol 2018
564
9


Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
Dass S Vinay, Elizabeth P Ryan, Graham Pawelec, Wamidh H Talib, John Stagg, Eyad Elkord, Terry Lichtor, William K Decker, Richard L Whelan, H M C Shantha Kumara,[...]. Semin Cancer Biol 2015
732
9

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
9

PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Y Latchman, C R Wood, T Chernova, D Chaudhary, M Borde, I Chernova, Y Iwai, A J Long, J A Brown, R Nunes,[...]. Nat Immunol 2001
9

Therapeutic cancer vaccines.
Mansi Saxena, Sjoerd H van der Burg, Cornelis J M Melief, Nina Bhardwaj. Nat Rev Cancer 2021
186
9

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova, Clemens Mayer, Mirjana Efremova, Dietmar Rieder, Hubert Hackl, Zlatko Trajanoski. Cell Rep 2017
9

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar,[...]. N Engl J Med 2019
9

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal,[...]. N Engl J Med 2021
418
9

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Padmanee Sharma, Margaret K Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N Pillai, Patrick A Ott, Filippo de Braud, Michael Morse,[...]. Lancet Oncol 2016
443
9

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, Ragini R Kudchadkar, Natalie J Miller, Lakshmanan Annamalai, Sneha Berry, Elliot K Chartash, Adil Daud, Steven P Fling,[...]. N Engl J Med 2016
790
9

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Michael R Migden, Danny Rischin, Chrysalyne D Schmults, Alexander Guminski, Axel Hauschild, Karl D Lewis, Christine H Chung, Leonel Hernandez-Aya, Annette M Lim, Anne Lynn S Chang,[...]. N Engl J Med 2018
660
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.